Post-CA Neuroprotection With Magnesium

Launched by NYU LANGONE HEALTH · Jun 7, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Post-CA Neuroprotection With Magnesium," is exploring the use of magnesium sulfate as a treatment to protect the brain after someone has experienced a cardiac arrest and regained their heartbeat (known as Return of Spontaneous Circulation, or ROSC). The main goals of the study are to see if giving magnesium is safe and to measure certain markers in the blood that can indicate brain injury. This study is in its early stages, and researchers hope to gather information that will help design a larger trial in the future.

To be eligible for this study, participants must be adults aged 65 to 85 who have just regained circulation after a cardiac arrest within the last two hours. However, people who have had traumatic cardiac arrests, are younger than 18 or older than 85, or have other specific medical conditions will not be included. If someone participates, they can expect to receive magnesium treatment while being closely monitored for safety and brain health indicators. It's important to note that this trial is not currently recruiting participants, and it aims to lay the groundwork for future research in this area.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Documented post-cardiac arrest patient with Return of Spontaneous Circulation (ROSC) achieved \<2 hours prior to recruitment
• Exclusion Criteria:
• • Age \< 18 years or \> 85 years
• • Traumatic cardiac arrests
• • Unsustained ROSC (\<20 minutes)
• • Patient who is responsive/able to follow motor commands within 1 hour of achieving ROSC
• • Plan for withdrawal of life support within 72 hours of ROSC
• • Known pregnant women at the time of the cardiac arrest
• • Known prisoners at the time of the cardiac arrest
• • Subjects who have a medical o social condition that would make them inappropriate for the study based on the PI's or clinical team judgement.